Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jake Tempo

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
BMC Urology|November 23, 2023
Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507)Jake Tempo, Damien Bolton, Michael O'Callaghan
BJUI Compass|June 14, 2024
Contemporary status of diagnostic endoluminal ultrasound and optical coherence tomography in the ureterSamuel Sii, Jeremy Bolton, Jake Tempo, et al.
Cancer Epidemiology|December 5, 2022
Global changes in bladder cancer mortality in the elderlyJake Tempo, Ting Wai Yiu, Joseph Ischia, et al.
Translational Andrology and Urology|November 13, 2025
Large stone in neobladder: percutaneous neocystolithotomyHaidar Al Saffar, Thirisha Radhakrishnan, Mohammadmehdi Adhami, et al.
Prostate International|February 2, 2026
Time to castrate the cost? the rising expense of chemical castration for the management of prostate cancerAlice Thomson, Haidar Al Saffar, Jake Tempo, et al.
Cancer Epidemiology|March 11, 2020
Bladder, penile, renal pelvis and testis cancers: A population based analysis of incidence and survival 1977-2013Jake Tempo, Callum Logan, Michael O'Callaghan, et al.
European Urology Oncology|September 26, 2022
Long-term Health-related Quality of Life in Patients on Active Surveillance for Prostate Cancer: A Systematic ReviewDaryl Thompson, Jonathan G Bensley, Jake Tempo, et al.
BJU International|April 10, 2025
Radical cystectomy mortality in older patients: a systematic review and meta-analysisJake Tempo, Sulleyman Felemban, Kirby R Qin, et al.
BJU International|November 28, 2024
Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mLSamuel Sii, Nathan Papa, Ting Wai Yiu, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
BMC Urology|November 23, 2023
Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507)Jake Tempo, Damien Bolton, Michael O'Callaghan
BJUI Compass|June 14, 2024
Contemporary status of diagnostic endoluminal ultrasound and optical coherence tomography in the ureterSamuel Sii, Jeremy Bolton, Jake Tempo, et al.
Cancer Epidemiology|December 5, 2022
Global changes in bladder cancer mortality in the elderlyJake Tempo, Ting Wai Yiu, Joseph Ischia, et al.
Translational Andrology and Urology|November 13, 2025
Large stone in neobladder: percutaneous neocystolithotomyHaidar Al Saffar, Thirisha Radhakrishnan, Mohammadmehdi Adhami, et al.
Prostate International|February 2, 2026
Time to castrate the cost? the rising expense of chemical castration for the management of prostate cancerAlice Thomson, Haidar Al Saffar, Jake Tempo, et al.
Cancer Epidemiology|March 11, 2020
Bladder, penile, renal pelvis and testis cancers: A population based analysis of incidence and survival 1977-2013Jake Tempo, Callum Logan, Michael O'Callaghan, et al.
European Urology Oncology|September 26, 2022
Long-term Health-related Quality of Life in Patients on Active Surveillance for Prostate Cancer: A Systematic ReviewDaryl Thompson, Jonathan G Bensley, Jake Tempo, et al.
BJU International|April 10, 2025
Radical cystectomy mortality in older patients: a systematic review and meta-analysisJake Tempo, Sulleyman Felemban, Kirby R Qin, et al.
BJU International|November 28, 2024
Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mLSamuel Sii, Nathan Papa, Ting Wai Yiu, et al.
Pageof 1